NCT03430843 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 256
- group Id
- BG001
- value
- 256
- group Id
- BG002
- value
- 512
- units
- Participants
- groups
- description
- Tislelizumab 200 mg intravenously (IV) on Day 1 every 21 days until disease progression, unacceptable toxicity, or other discontinuation criteria were met.
- id
- BG000
- title
- Tislelizumab
- description
- Investigator choice of either paclitaxel 135-175 mg /m² on Day 1 IV every 21 days or 80-100 mg/m\^2 on a weekly schedule; docetaxel 75 mg/m\^2 IV on Day 1 every 21 days; or irinotecan 125 mg/m\^2 IV on Days 1 and 8 every 21 days
- id
- BG001
- title
- Investigator Chosen Chemotherapy
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 8.41
- value
- 61.8
- group Id
- BG001
- spread
- 8.02
- value
- 61.8
- group Id
- BG002
- spread
- 8.21
- value
- 61.8
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 39
- group Id
- BG001
- value
- 41
- group Id
- BG002
- value
- 80
- title
- Female
- measurements
- group Id
- BG000
- value
- 217
- group Id
- BG001
- value
- 215
- group Id
- BG002
- value
- 432
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 4
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 252
- group Id
- BG001
- value
- 252
- group Id
- BG002
- value
- 504
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 4
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 201
- group Id
- BG001
- value
- 207
- group Id
- BG002
- value
- 408
- title
- Asian
- measurements
- group Id
- BG000
- value
- 53
- group Id
- BG001
- value
- 44
- group Id
- BG002
- value
- 97
- title
- White or Caucasian
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Not Reported
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- Unknown
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Other
- title
- Race
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 66
- group Id
- BG001
- value
- 61
- group Id
- BG002
- value
- 127
- title
- 0
- measurements
- group Id
- BG000
- value
- 190
- group Id
- BG001
- value
- 195
- group Id
- BG002
- value
- 385
- title
- 1
- description
- Measure Description: ECOG performance status is used by doctors and researchers to assess how a participant's disease is progressing, assess how the disease affects the daily living activities of the participant and determine appropriate treatment and prognosis. 0 = Fully Active (Most Favorable Activity); 1 = Restricted activity but ambulatory; 2 = Ambulatory but unable to carry out work activities; 3 = Limited Self-Care; 4 = Completely Disabled, No self-care (Least Favorable Activity)
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status Score
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 80
- group Id
- BG001
- value
- 62
- group Id
- BG002
- value
- 142
- title
- vCPS >= 10%
- measurements
- group Id
- BG000
- value
- 100
- group Id
- BG001
- value
- 122
- group Id
- BG002
- value
- 222
- title
- vCPS < 10%
- measurements
- group Id
- BG000
- value
- 76
- group Id
- BG001
- value
- 72
- group Id
- BG002
- value
- 148
- title
- Missing
- description
- Measure Description: Programmed death ligand 1 (PD-L1) positive is defined as visually-estimated Combined Positive Score (vCPS) \>= 10%, PD-L1 negative is defined as vCPS \< 10%, PD-L1 missing refers to the participants without sample collection, not evaluable at baseline, or scored with unqualified sample. Note terminology was updated from vCPS to Tumor Area Positivity (TAP) score in manuscripts.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- PD-L1 Expression Status
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 256
- group Id
- BG001
- value
- 256
- group Id
- BG002
- value
- 512
- units
- Participants
- groups
- description
- Tislelizumab 200 mg intravenously (IV) on Day 1 every 21 days until disease progression, unacceptable toxicity, or other discontinuation criteria were met.
- id
- BG000
- title
- Tislelizumab
- description
- Investigator choice of either paclitaxel 135-175 mg /m² on Day 1 IV every 21 days or 80-100 mg/m\^2 on a weekly schedule; docetaxel 75 mg/m\^2 IV on Day 1 every 21 days; or irinotecan 125 mg/m\^2 IV on Days 1 and 8 every 21 days
- id
- BG001
- title
- Investigator Chosen Chemotherapy
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 8.41
- value
- 61.8
- group Id
- BG001
- spread
- 8.02
- value
- 61.8
- group Id
- BG002
- spread
- 8.21
- value
- 61.8
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 39
- group Id
- BG001
- value
- 41
- group Id
- BG002
- value
- 80
- title
- Female
- measurements
- group Id
- BG000
- value
- 217
- group Id
- BG001
- value
- 215
- group Id
- BG002
- value
- 432
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 4
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 252
- group Id
- BG001
- value
- 252
- group Id
- BG002
- value
- 504
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 4
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 201
- group Id
- BG001
- value
- 207
- group Id
- BG002
- value
- 408
- title
- Asian
- measurements
- group Id
- BG000
- value
- 53
- group Id
- BG001
- value
- 44
- group Id
- BG002
- value
- 97
- title
- White or Caucasian
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Not Reported
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- Unknown
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Other
- title
- Race
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 66
- group Id
- BG001
- value
- 61
- group Id
- BG002
- value
- 127
- title
- 0
- measurements
- group Id
- BG000
- value
- 190
- group Id
- BG001
- value
- 195
- group Id
- BG002
- value
- 385
- title
- 1
- description
- Measure Description: ECOG performance status is used by doctors and researchers to assess how a participant's disease is progressing, assess how the disease affects the daily living activities of the participant and determine appropriate treatment and prognosis. 0 = Fully Active (Most Favorable Activity); 1 = Restricted activity but ambulatory; 2 = Ambulatory but unable to carry out work activities; 3 = Limited Self-Care; 4 = Completely Disabled, No self-care (Least Favorable Activity)
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status Score
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 80
- group Id
- BG001
- value
- 62
- group Id
- BG002
- value
- 142
- title
- vCPS >= 10%
- measurements
- group Id
- BG000
- value
- 100
- group Id
- BG001
- value
- 122
- group Id
- BG002
- value
- 222
- title
- vCPS < 10%
- measurements
- group Id
- BG000
- value
- 76
- group Id
- BG001
- value
- 72
- group Id
- BG002
- value
- 148
- title
- Missing
- description
- Measure Description: Programmed death ligand 1 (PD-L1) positive is defined as visually-estimated Combined Positive Score (vCPS) \>= 10%, PD-L1 negative is defined as vCPS \< 10%, PD-L1 missing refers to the participants without sample collection, not evaluable at baseline, or scored with unqualified sample. Note terminology was updated from vCPS to Tumor Area Positivity (TAP) score in manuscripts.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- PD-L1 Expression Status
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle